Impact of Extent of Lymphadenectomy on Survival in Patients With Endometrial Cancer: A Matched Cohort Study.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 28 01 2020
revised: 12 02 2020
accepted: 13 02 2020
entrez: 6 3 2020
pubmed: 7 3 2020
medline: 16 4 2020
Statut: ppublish

Résumé

This study aimed to determine whether a pelvic and para-aortic lymphadenectomy (PPAL) improves survival compared with a pelvic lymphadenectomy (PL) in patients with endometrial cancer. Data from all women operated for endometrial cancer between 1998 and 2013 were extracted from the Surveillance, Epidemiology and End Results database. Women treated with PL were matched with those treated with PPAL according to age and risk of recurrence. The primary endpoint was disease-specific survival (DSS). A total of 1015 patients who underwent PL were matched with 1015 patients who underwent PPAL. The 3-year DSS probabilities for patients at intermediate- and high-risk (IHR) of recurrence were similar in the PPAL group and the PL group. Multivariate analysis of prognostic factors indicated that in patients with an IHR of recurrence, PPAL did not reduce the risk of death compared with PL. For patients with an IHR of recurrence, the extent of lymphadenectomy does not impact DSS.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
This study aimed to determine whether a pelvic and para-aortic lymphadenectomy (PPAL) improves survival compared with a pelvic lymphadenectomy (PL) in patients with endometrial cancer.
PATIENTS AND METHODS METHODS
Data from all women operated for endometrial cancer between 1998 and 2013 were extracted from the Surveillance, Epidemiology and End Results database. Women treated with PL were matched with those treated with PPAL according to age and risk of recurrence. The primary endpoint was disease-specific survival (DSS).
RESULTS RESULTS
A total of 1015 patients who underwent PL were matched with 1015 patients who underwent PPAL. The 3-year DSS probabilities for patients at intermediate- and high-risk (IHR) of recurrence were similar in the PPAL group and the PL group. Multivariate analysis of prognostic factors indicated that in patients with an IHR of recurrence, PPAL did not reduce the risk of death compared with PL.
CONCLUSION CONCLUSIONS
For patients with an IHR of recurrence, the extent of lymphadenectomy does not impact DSS.

Identifiants

pubmed: 32132058
pii: 40/3/1563
doi: 10.21873/anticanres.14103
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1563-1570

Informations de copyright

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Lea Pauly (L)

Gynecologic Oncology, Bichat University Hospital, Paris Diderot University, Paris, France lea.pauly64@gmail.com.

Louise Benoit (L)

Gynecologic Oncology, Bichat University Hospital, Paris Diderot University, Paris, France.

Martin Koskas (M)

Gynecologic Oncology, Bichat University Hospital, Paris Diderot University, Paris, France.
EA 7285, Versailles Saint Quentin Université, Montigny Le Bretonneux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH